Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASF 1057 cream 0.5% for seborrhoeic dermatitis
2007-004627-38Phase 3Completed
- Sponsor
- Astion Pharma
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ASF-1057 and monoctanoin in seborrheic dermatitis (SD) (3 arms), sponsored by Astion Pharma. Primary endpoints: Responder rate at Visit 5 and Pairwise differences in responder proportions. Started Sep 2007; status: completed.
02
Drugs
ASF-1057monoctanoin
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on 2007-004627-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004627-38.